J. Charles Homcy's Insider Trades & SAST Disclosures
J. Charles Homcy's most recent trade in Maze Therapeutics Inc. was a trade of 169,405 Series C Preferred Stock done . Disclosure was reported to the exchange on Feb. 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern J. Charles Homcy.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Maze Therapeutics Inc. | Charles J. Homcy | Director | 03 Feb 2025 | 169,405 | 0 | - | - | Series C Preferred Stock | ||
| Maze Therapeutics Inc. | Charles J. Homcy | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 80,385 | 0 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc. | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 80,385 | 80,385 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc. | Charles J. Homcy | Director | 03 Feb 2025 | 72,727 | 0 | - | - | Series B Preferred Stock | ||
| Maze Therapeutics Inc. | Charles J. Homcy | Director | 03 Feb 2025 | 71,564 | 7,422 | - | - | Series D-1 Preferred Stock | ||
| Maze Therapeutics Inc. | Charles J. Homcy | Director | 03 Feb 2025 | 71,564 | 0 | - | - | Series D-1 Preferred Stock | ||
| Maze Therapeutics Inc. | Charles J. Homcy | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 46,675 | 0 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc. | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 46,675 | 46,675 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc. | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 45,638 | 45,638 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc. | Charles J. Homcy | Director | 03 Feb 2025 | 20,717 | 58,047 | - | - | Common Stock | ||
| Maze Therapeutics Inc. | Charles J. Homcy | Director | 03 Feb 2025 | 8,807 | 37,330 | - | - | Common Stock | ||
| Maze Therapeutics Inc. | Charles J. Homcy | Director | 03 Feb 2025 | 7,422 | 7,422 | - | - | Common Stock | ||
| Maze Therapeutics Inc. | Charles J. Homcy | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Feb 2025 | 5,704 | 0 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc. | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 5,704 | 5,704 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 26,014 | 26,014 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Homcy J. Charles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 3,760 | 1,231,594 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 3,760 | 0 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | J. Charles Homcy | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.21 per share. | 16 Feb 2024 | 1,509 | 1,230,085 (0%) | 0% | 37.2 | 56,150 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2023 | 3,760 | 1,225,838 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2023 | 3,760 | 7,520 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.80 per share. | 16 Aug 2023 | 1,301 | 1,224,537 (0%) | 0% | 29.8 | 38,770 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 51,501 | 51,501 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 3,759 | 11,280 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 3,759 | 1,222,127 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.09 per share. | 16 May 2023 | 1,300 | 1,220,827 (0%) | 0% | 14.1 | 18,317 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 3,760 | 15,039 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 3,760 | 1,219,902 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.64 per share. | 16 Feb 2023 | 1,534 | 1,218,368 (0%) | 0% | 12.6 | 19,390 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 3,760 | 22,559 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 3,760 | 1,210,742 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.08 per share. | 16 Aug 2022 | 1,287 | 1,209,455 (0%) | 0% | 11.1 | 14,260 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 104,921 | 104,921 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2022 | 3,759 | 1,208,523 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2022 | 3,759 | 26,319 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.74 per share. | 16 May 2022 | 1,541 | 1,206,982 (0%) | 0% | 6.7 | 10,386 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 30,078 | 30,078 | - | - | Restricted Stock Units | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2021 | 55,011 | 55,011 | - | - | Stock Option (right to buy) | |
| Pliant Therapeutics Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 13,286 | 13,286 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 38,895 | 38,895 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 1,521 | 1,205,288 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 71.91 per share. | 01 Mar 2021 | 524 | 1,204,764 (0%) | 0% | 71.9 | 37,681 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director, Chairman of Pharmaceuticals | Sale of securities on an exchange or to another person at price $ 41.00 per share. | 16 Oct 2020 | 10,256 | 1,203,767 (0%) | 0% | 41 | 420,496 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director, Chairman of Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2020 | 10,256 | 260,207 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director, Chairman of Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.00 per share. | 16 Oct 2020 | 10,256 | 1,214,023 (0%) | 0% | 17 | 174,352 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director, Chairman of Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.00 per share. | 30 Sep 2020 | 10,000 | 1,213,767 (0%) | 0% | 17 | 170,000 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director, Chairman of Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2020 | 10,000 | 270,463 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director, Chairman of Pharmaceuticals | Sale of securities on an exchange or to another person at price $ 38.00 per share. | 30 Sep 2020 | 10,000 | 1,203,767 (0%) | 0% | 38 | 380,000 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director, Chairman of Pharmaceuticals | Sale of securities on an exchange or to another person at price $ 36.68 per share. | 25 Sep 2020 | 65,661 | 1,237,363 (0%) | 0% | 36.7 | 2,408,590 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director, Chairman of Pharmaceuticals | Sale of securities on an exchange or to another person at price $ 37.50 per share. | 25 Sep 2020 | 18,200 | 1,203,767 (0%) | 0% | 37.5 | 682,500 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director, Chairman of Pharmaceuticals | Sale of securities on an exchange or to another person at price $ 37.47 per share. | 25 Sep 2020 | 15,396 | 1,221,967 (0%) | 0% | 37.5 | 576,865 | Common Stock |
| BridgeBio Pharma Inc | Charles J. Homcy | Director, Chairman of Pharmaceuticals | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2020 | 112,422 | 112,422 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Charles J. Homcy | Director, Chairman of Pharmaceuticals | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Apr 2020 | 40,000 | 1,302,291 (1%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges